Medical Oncology

, Volume 14, Issue 2, pp 91–98 | Cite as

Use of granulocyte-macrophage colony stimulating factor in the treatment of prolonged haematopoietic dysfunction after chemotherapy alone or chemotherapy plus bone marrow transplantation

  • Rainier Dierdorf
  • Ulrich Kreuter
  • Thomas C. Jones
Paper

Abstract

This study evaluates the use of granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with prolonged haematopoietic dysfunction (>21 days) after using chemotherapy to treat cancer. One hundred and seven patients were identified who had a leucocyte count below 1000 cells/mm3 more than 21 days after start of chemotherapy (81 patients) or after bone marrow transplantation (BMT) (26 patients). There were 66 males and 40 females ranging in age from 4.5 to 82 years. The duration of aplasia was 48 ± 43 days in the chemotherapy alone group, and 79 ± 57 days in the post BMT group. Over 80% of the patients had haematologic malignancies and 70% had an infection prior to the start of the cytokine. Patients received 5 μg GM-CSF/kg1 body weight daily i.v. or s.c. for 14 ± 11 days in the chemotherapy group and 20 ± 26 days in the BMT group. Sixty percent of chemotherapy patients and 58% of BMT patients had a haematological response to treatment (leucocyte count >2000 cells/mm3. Median times to haematologic recovery were 7 days in the chemotherapy group and 10 days in the BMT group. There was a significant reduction in the number of infections (73% to 28% in the chemotherapy group). Clinical responses in the two groups were 55% and 50%, respectively. No severe, drug-related adverse events were reported and no evidence of stimulation of malignant clones was observed. It is concluded that GM-CSF is effective and well tolerated in patients with prolonged bone marrow dysfunction after chemotherapy or BMT. Although results from an open-label trial must be viewed with caution, this observation confirms the value and safety of GM-CSF therapy in patients with this severe, and often fatal, condition.

Keywords

bone marrow failure bone marrow transplant chemotherapy cytokine GM-CSF haematologic malignancies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nemunaitis, J., Singer, J.W., Duckner, C.D., Durnam, D., Epstein, C., Hill, R., Storb, R., Thomas, E.D. and Appelbaum, F.R. (1990) Use of Recombinant Human Granulocyte-Macrophage Colony — Stimulating Factor in Graft Failure after Bone Marrow Transplantation.Blood 76, 245–53.PubMedGoogle Scholar
  2. 2.
    Weisdorf, D.J., Verfaillie, C.M., Davies, S.M., Filpovich, A.H, Wagner, J.E. Jr, Miller, J.S., Burroughs, J., Ramsay, M.K.C., Kersey, J.H., McGlave, P.B. and Blazer, B.R. (1995) Hematopoietic Growth Factors for Graft Failure after Bone Marrow Transplantation: A Randomized Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Sequential GM-CSF Plus Granulo-cyte-CSF.Blood 85, 3452–6.PubMedGoogle Scholar
  3. 3.
    Gorin, N.-C., Laporte, J.P. and Fouillard, L. (1995) Granulocyte-Macrophage Colony-Stimulating Factor as an Adjunct to Autologous Bone Marrow Transplantation in Hematology: Considerations on Increased Safety in the Transplant Ward. In N.I. Nissen and T.M. Dexter (eds)Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Current Uses and Future Applications, pp. 38–45. Proc. Int. Symp. September 9–11, 1993. Cheshire: Pennine Press.Google Scholar
  4. 4.
    Sierra, J., Terol, M.J., Urbano-Isizua, A., Rovira, M., Marin, P., Carreras, E., Batlle, M. and Rozman, C. (1994) Different Responses to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Primary and Secondary Graft Failure after Bone Marrow Transplantation.Exp. Hematol. 22, 566–72.PubMedGoogle Scholar
  5. 5.
    Gerhartz, H.H., Engelhart, M., Meusers, P., Brittinger, G., Wilmanns, W., Scholimok, G., Mueller, P., Huhn, D., Musch, R., Siegert, W., Gerhatz, D., Hartlapp, J.H., Thiel, E., Huber, C., Peschl, C., Spann, W., Emmerich, B., Schadek, C., Westerhausen, M., Pees, H.W., Radtke, H., Engert, A., Terhardt, E., Schick, H., Binder, T., Fuchs, R., Hasford, J., Brandmeier, R., Stern, A., Jones, T.C., Ehrlich, F.J., Stein, H., Parwaresch, M., Tiemann, M. and Lennert, K. (1993) Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) as Adjunct to Induction Treatment of High-Grade Malignant Non-Hodgkin’s Lymphomas.Blood 82, 2329–39.PubMedGoogle Scholar
  6. 6.
    Nemunaitis, J., Rabinowe, S.N., Singer, J.W., Bierman, P.J., Vose, J.M., Freedman, A.S., Onetto, N., Gillis, S., Oette, D., Gold, M., Buckner, D., Hansen, J.A., Ritz, J., Appelbuaum, F.R., Armitage, J.O. and Nadler, I.M. (1991) Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer.New Engl. J. Med. 324, 1773–78.PubMedCrossRefGoogle Scholar
  7. 7.
    Dreger, P., Suttorp, M., Haferlach, T., Loeffler, H., Schmitz, N. and Schroyens, W. (1993). Allogeneic Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells for Treatment of Engraftment Failure after Bone Marrow Transplantation.Blood 81, 1404–7.PubMedGoogle Scholar
  8. 8.
    Vose, J.M., Bierman, P.J., Kessinger, A., Cocda, P.F., Anderson, J., Oldman, F.B., Epstein, C. and Armitage, J.O. (1991) The Use of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for the Treatment of Delayed Engraftment Following High Dose Therapy and Autologous Stem Cell Transplantation for Lymphoid Malignancies.Bone Marr. Transpl. 7, 139–43.Google Scholar
  9. 9.
    Kingmann, H.-G., Eaves, A.C., Barnett, M.J., Reece, D.E., Shepherd, J.D., Belch, A.R., Brandwein, J.M., Langleben, A., Koch, P.A. and Phillips, G.L. (1990) Recombinant GM-CSF in Patients with Poor Graft Function after Bone Marrow Transplantation.Clin. Invest. Med. 13, 77–81.Google Scholar
  10. 10.
    Ippoliti, C., Przepiorka, D., Giralt, S., Andersson, B.S., Wallerstein, R.O., Gutterman, J., Deisseroth, A.B. and Champlin, R.E. (1993) Low-Dose Non-Glycosylated rhGM-CSF is Effective for the Treatment of Delayed Hematopoietic Recovery after Autologous Marrow or Peripheral Blood Stem Cell Transplantation.Bone Marr. Transpl. 11, 55–9.Google Scholar
  11. 11.
    Crump, M., Couture, F., Kovacs, M., Saragosa, R., McCrae, J., Brandwein, J., Huebsch, L., Beauregard-Zollinger, L. and Keating, A. (1993) Interleukin-3 Followed by GM-CSF for Delayed Engraftment after Autologous Bone Marrow Transplantation.Exp. Hematol. 21, 405–10.PubMedGoogle Scholar
  12. 12.
    Bierman, P., Appelbaum, F., Oette, D., Gillis, S., Armitage, J. and Nemunaitis, J. (1992) Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Engraftment Failure (EF) Following Autologous (Auto) or Allogeneic (Allo) Bone Marrow Transplantation (BMT).Blood 80, 1065, 269a.Google Scholar
  13. 13.
    Rosenthal, N.S. and Farhi, D.C. (1994) Failure to Engraft after Bone Marrow Transplantation: Bone Marrow Morphologic Findings.Am. J. Clin. Pathol. 102, 821–4.PubMedGoogle Scholar
  14. 14.
    Foucar, K. (1994) Bone Marrow Histiocytosis and Autologous Graft Failure: Possible Implications.Am. J. Clin. Pathol. 102, 713–4.PubMedGoogle Scholar
  15. 15.
    Rowe, J.M., Andersen, J.W., Mazza, J.J., Bennett, J.M., Paietta, E., Hayes, F.A., Oette, D., Cassileth, P.A., Stadtmauer E.A. and Wiernik, P.H. (1995) Randomized Placebo-Controlled Phase III Study of Granulocyte-Macrophage Colony-Stimulating Factor in Adult Patients (>55 to 70 Years of Age) With Acute Myelogenous Leukemia: A Study of the Eastern Cooperative Oncology Group (E1490).Blood 86, 457–62.PubMedGoogle Scholar
  16. 16.
    Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L., Schiffer, CA. for Cancer and Leukemia Group B. (1995) Granulocyte-Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia.New Engl. J. Med. 332, 1671–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Nemunaitis, J. (1993) Growth Factors in Allogeneic Transplantation.Semin. Oncol. 20, Suppl 6, 96–101.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1997

Authors and Affiliations

  • Rainier Dierdorf
    • 1
  • Ulrich Kreuter
    • 2
  • Thomas C. Jones
    • 3
  1. 1.Sandoz Pharma LtdBasleSwitzerland
  2. 2.Consult AGBernSwitzerland
  3. 3.Clinical Research ConsultantsBasleSwitzerland

Personalised recommendations